California-based venture capital firm Versant Ventures yesterday announced the launch of Pep2Tango Therapeutics, a start-up focused on innovative, next-generation weight loss therapies. Proceeds from ...

Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the significant, undisclosed round will ...

POTOMAC, Md. — Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the significant, ...

POTOMAC, Md.--(BUSINESS WIRE)--Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the ...

POTOMAC, Md.--(BUSINESS WIRE)--Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the ...

VC firm Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with multiple targets in hopes of overcoming limitations tied to GLP-1 treatments.

Biotech company creator Versant Ventures has launched a new startup with an ambitious plan to combine four different ways of treating obesity into a single drug. The startup, Pep2Tango Therapeutics, ...

Download the free “New Cannabis Ventures” app on the iOS App Store or Google Play and get real-time push notifications straight to your phone on the latest breaking news and exclusives published.

Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...

Versant Ventures led the round and was joined by Novo Holdings, which provided seed investment, SR One, Pictet, entities associated with KKR and Broadview Ventures, and the Export and Investment Fund ...